Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

2.1 Niraparib (Zejula, GlaxoSmithKline) has a marketing authorisation in the UK 'as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages 3 and 4) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price is £4,500 for 56 100‑mg tablets (excluding VAT; BNF online accessed November 2020). The company has a commercial arrangement. This makes niraparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.